Kevin McCulloch - 01 Aug 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
01 Aug 2024
Net transactions value
$0
Form type
4
Filing time
02 Aug 2024, 17:22:39 UTC
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +150,000 +10% $0.000000 1,601,953 01 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +200,000 $0.000000 200,000 01 Aug 2024 Common Stock 200,000 $2.43 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The award will vest in full on the two-year anniversary of the grant date.
F2 Upon exercise, the Stock Appreciation Right will be settled in cash.

Remarks:

President and Chief Operating Officer